Virtual Meeting to be held on April 23 hosted by Lake Street. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS ...

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are covering the company, MarketBeat ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full ...

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.

SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...